Immunization of cynomolgus macaques with the envelope glycoprotein gp130 of HIV-2ben confers protection against the homologous but not the heterologous virus challenge with HIV-2SBL-6999.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Immunization of cynomolgus macaques with the envelope glycoprotein gp130 of HIV-2ben confers protection against the homologous but not the heterologous virus challenge with HIV-2SBL-6999.

Symp Nonhum Primate Models AIDS. 1992 Nov 17-20;10:abstract no. 123. Unique Identifier : AIDSLINE PRIM10/93200963
Luke W; Voss G; Stahl-Hennig C; Coulibaly C; Petry H; Hunsmann G; German Primate Center, Gottingen.

Abstract: Nine cynomolgus monkeys were immunized over a period of 52 weeks with gp130 of HIV-2ben mixed with KLH containing 1.1 mg of purified gp130 per animal. For the first 3 immunizations we used incomplete Freund's adjuvant. Because of severe inflammatory reactions antigen was adsorbed to aluminium hydroxide for the later 4 immunizations. The vaccinated animals along with 6 controls were challenged with 10 MID50 of HIV-2ben. At the time of challenge, the vaccinees had developed anti gp130 antibody titers of about 1 to 1.5 x 10(5) and 4 animals exhibited neutralizing antibodies. After challenge, the 9 vaccinees showed neither a secondary immune response nor a transient viraemia. Four of the vaccinees were positive in PCR and 1 of these animals had developed CTL activity. All 6 controls developed a primary antibody response to HIV-2ben, 5 were positive in PCR, 4 showed CTL activity and 2 were transiently viraemic. The protected 5 vaccinees were reimmunized once and challenged with 10 MID50 of the heterologous HIV-2SBL-6999 together with one naive control. Four weeks later, all animals were PCR positive. The control animal developed a primary immune response and 4 of the 5 vaccinees a transient viraemia followed by a secondary antibody response. One of the vaccinees showed neither a viraemia nor a secondary immune response. Thus immunization with native gp130 micelles from HIV-2ben could protect 5/9 monkeys against a homologous virus challenge. Infection with the heterologous virus HIV-2SBL-6999 could not be prevented, but in one animal virus replication was suppressed.

Keywords: Animal *Antibody Formation *Immunization Macaca fascicularis Neutralization Tests Polymerase Chain Reaction Simian Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/PREVENTION & CONTROL SIV/GENETICS/*IMMUNOLOGY/ISOLATION & PURIF Vaccines, Synthetic/*PHARMACOLOGY Viral Envelope Proteins/*IMMUNOLOGY/PHARMACOLOGY Viral Vaccines/*PHARMACOLOGY ABSTRACT
930630
M9361057

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .